Xilio Therapeutics (XLO) Notes Payables (2020 - 2023)

Xilio Therapeutics (XLO) has 3 years of Notes Payables data on file, last reported at $3.3 million in Q4 2023.

• For the quarter ending Q4 2023, Notes Payables fell 50.28% year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2023 stood at $3.3 million (down 50.28% YoY), and the FY2023 full-year result was $3.3 million, down 50.28% from the prior year.
• Notes Payables eased to $3.3 million in Q4 2023, from $5.0 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $7.1 million in Q2 2023 to a low of $1.7 million in Q1 2022.
• A 3-year average of $4.6 million and a median of $5.0 million in 2023 frame the typical range for Notes Payables.
• Peak annual rise in Notes Payables reached 299.94% in 2023, while the deepest fall reached 50.28% in 2023.
• Tracing XLO's Notes Payables over 3 years: stood at $2.3 million in 2020, then soared by 185.77% to $6.7 million in 2022, then slumped by 50.28% to $3.3 million in 2023.
• Business Quant data shows XLO's Notes Payables at $3.3 million in Q4 2023, $5.0 million in Q3 2023, and $7.1 million in Q2 2023.